Prevalence and characteristics of resistant hypertension at primary clinics in Korea: a nationwide cross-sectional study by Kwang No Lee et al.
RESEARCH Open Access
Prevalence and characteristics of resistant
hypertension at primary clinics in Korea: a
nationwide cross-sectional study
Kwang No Lee1, Jin Oh Na2, Cheol Ung Choi2, Hong Euy Lim2, Jin Won Kim2, Eung Ju Kim2, Seung-Woon Rha2,
Hong Seog Seo2, Dong Joo Oh2 and Chang Gyu Park2*
Abstract
Background: Although resistant hypertension (RH) is known to be associated with higher rates of cardiovascular
events than is non-RH, there are no reported data on the prevalence of RH in Korean patients. We evaluated the
prevalence and characteristics of RH among hypertensive patients treated at primary clinics in Korea.
Methods: Between August 2010 and January 2011, 247 primary care physicians enrolled 3088 patients with
essential hypertension. We acquired demographic and anthropometric data using a questionnaire, evaluated
blood pressure, and conducted a variety of laboratory tests using serum and urine. RH was defined as systolic
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg with the use of three antihypertensive
agents of different classes, including a diuretic, or controlled hypertension with the use of four or more
medications.
Results: We analyzed 3088 patients with hypertension, 48.3 % of whom were men. The mean age of patients was
64.3 ± 11.3 years and the prevalence of RH was 7.9 %. Patients with RH were more likely to be men, and to have higher
waist circumference, increased blood levels of HbA1c, triglycerides, and serum creatinine, lower blood levels of high-
density lipoprotein (HDL), and higher rates of current smoker, history of heart failure or coronary artery disease, and
electrocardiographic left ventricular hypertrophy (LVH), than were patients with non-RH (all comparisons,
P < 0.05). In the multivariate analysis, RH was shown to be significantly associated with the following conditions:
presence of electrocardiographic LVH (odds ratio [OR] 2.23, 95 % confidence interval [CI] 1.34–3.71), current smoker
(OR 1.75, 95 % CI 1.27–2.40), renal impairment (OR 1.65, 95 % CI 1.23–2.22), abdominal obesity (OR 1.60, 95 % CI
1.20–2.13), and cardiovascular diseases (OR 1.50, 95 % CI 1.04–2.17).
Conclusions: The prevalence of RH was relatively low at primary clinics in Korea compared with the prevalence
reported in other countries. RH was associated with electrocardiographically confirmed LVH, renal impairment, current
smoker, abdominal obesity, and cardiovascular diseases. These are the first reported data of RH in Korea. Our findings
may be helpful in the early detection and thorough clinical management of patients with RH at primary clinics.
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Background
Resistant hypertension (RH) was defined by the seventh
Joint National Committee as the failure to achieve a tar-
get blood pressure despite maintaining full doses of
three antihypertensive agents of different classes, one of
which should be a diuretic [1]. Following a 2008 state-
ment by the American Heart Association, controlled
hypertension using at least four medications is also con-
sidered as RH [2].
Although the specific prognostic implications of RH
have not been well evaluated, RH is frequently associated
with cardiovascular risk factors, such as older age, dia-
betes mellitus, obesity, obstructive sleep apnea, left ven-
tricular hypertrophy (LVH), and chronic kidney disease
[2, 3]. Among patients in a retrospective cohort study,
those with RH had an higher rate of cardiovascular
events, as shown by an adjusted hazard ratio of 1.47
(95 % confidence interval [CI], 1.33–1.62; P < 0.001),
over the mean follow-up period of 3.8 years than did
those with non-RH [4]. Therefore, precise statistical data
of RH and aggressive treatment of this condition may be
necessary to reduce cardiovascular events.
However, to our knowledge, the exact prevalence of
RH in Korea has yet to be reported. Patients who have
difficulty controlling their blood pressure or who are
suspected to have RH are usually referred from primary
clinics to the hospital, where cardiologists who specialize
in hypertension manage their care. Therefore, the inves-
tigation of the clinical management of RH in primary
clinics may be insufficient to capture the prevalence of
this disease, even though the prevalence of RH is report-
edly 11 ~ 21 % at tertiary facilities and 10 % at primary
clinics in the United States [5, 6].
Hypertension is often present as part of the metabolic
syndrome and is associated with insulin resistance.
Higher rates of diabetes mellitus or obesity may be
present in patients with RH compared with those who
have non-RH. Accurate information regarding the preva-
lence and outcome of RH is important for managing and
improving the prognosis of this condition. Identifying
and targeting high-risk patients with hypertension can
increase the cost effectiveness of primary clinics. There-
fore, we investigated the prevalence of RH and evaluated




Patients who were older than 18 years with essential
hypertension and who visited primary clinics in 2010
were eligible to participate in this cross-sectional study.
Patients were excluded if they had the following condi-
tions: secondary hypertension, white-coat hypertension,
acute myocardial infarction, unstable angina, acute phase
of stroke, peripheral artery disease, or uncontrolled dia-
betes mellitus (HbA1c > 9.0 %). Two hundred and forty-
seven physicians in 230 primary clinics participated in
this study through the network that was organized in a
previous investigation [7]. The primary clinic was chosen
randomly according to the proportion of the population
in each city or province. This study was approved by the
Institutional Review Board of the Korea University Guro
Hospital.
Physicians measured blood pressure using an elec-
tronic sphygmomanometer (OMRON MX-3, Omron
Healthcare, Kyoto, Japan). After the patient had been
seated quietly for 5 min, blood pressure was measured
with the right arm of the patient supported at the level
of the heart. We obtained two or three blood pressure
measurements, 30 s apart. If blood pressure was mea-
sured twice, the average value was assigned to the blood
pressure of the patient. If it was measured three times,
the second and the third values were used to calculate
the average of systolic and diastolic blood pressure.
Each patient enrolled in the study was given a self-
administered questionnaire in order to collect data on
demography, lifestyle, and a family history of hypertension
and cardiovascular disease. The physicians also recorded
anthropometrical parameters, such as comorbidities and
antihypertensive medications.
An 8-h fasting blood sample was collected for the
measurement of hemoglobin A1c, fasting plasma glu-
cose, and blood lipids. Urinary analysis was also per-
formed to measure albumin concentration in the spot
urine and the albumin/creatinine ratio was estimated to
compensate for variations in urinary concentration.
The body mass index (BMI) was calculated from the
patient’s height and weight. The waist circumference was
measured at the narrowest part of the waist between the
lowest rib and the iliac crest.
Definitions
The Eighth Joint National Committee defined hyperten-
sion as either office systolic blood pressure level of more
than 140 mmHg or diastolic blood pressure of less than
90 mmHg [8]. RH was defined as the failure to reach
target blood pressure despite full doses of an appropriate
three antihypertensive medications of different classes,
including a diuretic, or controlled hypertension that
required 4 or more medications [2].
Abdominal obesity was defined as waist circumference
of more than 90 cm for men and more than 85 cm for
women. Smoking was categorized as current, ex-smoker
of less than 1 year, or non-smoker, according to smoking
status. The presence of dyslipidemia was defined by low-
density lipoprotein (LDL) ≥ 130 mg/dL in patients with
hypertension, and also included cases already receiving
lipid-lowering agents [9]. Patients were considered to have
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diabetes mellitus if their fasting plasma glucose level
was ≥126 mg/dL, if their HbA1c level was ≥6.5 %, or if
they were taking oral hypoglycemic drugs or insulin.
Target organ damage was evaluated by electrocardio-
graphic LVH for the heart, by estimated glomerular filtra-
tion rate (GFR) of <60 mL/min/1.73 m2, and/or by an
albumin to creatinine ratio of ≥30 μg/mg. Renal impair-
ment was defined as having an estimated GFR < 60 mL/
min, as calculated by the Modification of Diet in Renal
Disease equation. Microalbuminuria was defined as an
albumin to creatinine ratio of 30 to 300 μg/mg [10]. Elec-
trocardiographic LVH was identified if the result of the
QRS duration multiplied by the Cornell voltage combin-
ation (R in aVL + S in V3, with 8 mm added in women)
was higher than 2440 mVms [11], or if Sokolow-Lyon
voltage (S in V1 + R in V5/6) was higher than 38 mm [12].
Cardiovascular disease included coronary artery dis-
ease, congestive heart failure, and stroke. The presence
of coronary artery disease was defined as acute myocar-
dial infarction or hospitalization with angina pectoris.
The presence of congestive heart failure was defined as
the need for hospitalization. Diagnosis of stroke was
necessary to confirm infarction demonstrated by com-
puted tomography or magnetic resonance imaging.
Statistical analysis
All statistical analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). Interval variables were
described as mean ± standard deviation. Nominal or
ordinal variables were described as proportions. Student’s
t-test or one way-ANOVA were used for continuous vari-
ables and chi-square test or Fisher exact test were used for
the categorical variables. Multivariate logistic regression
analysis was performed to determine independent clinical
predictors for RH in the stepwise forward selection pro-
cedure. All analyses were performed with 95 % confidence
intervals, and p-values of less than 0.05 were considered
statistically significant.
Results
Among 3122 recruited patients, 34 patients were ex-
cluded: 5 did not sign an informed consent form, 8 had
inadequate blood samples, and 21 provided no informa-
tion about antihypertensive medication (Fig. 1). There-
fore, 3088 patients were included in the analysis.
Baseline characteristics
The prevalence of RH among all hypertensive patients
was 7.9 % (N = 244). The mean age of the patients was
64.3 ± 11.3 years (Table 1) and 48.3 % of patients were
men. The average systolic blood pressure and diastolic
blood pressure of patients were 131.7 ± 15.2 mmHg and
79.4 ± 10.0 mmHg, respectively. On average, patients
were taking 1.84 ± 0.82 classes of medication, primarily
angiotensin-converting-enzyme (ACE) inhibitors or
angiotensin-II receptor blockers (ARBs, 70.0 %), followed
Fig. 1 Flow chart of the study: evaluation for confirmation of resistant hypertension. Among 3122 eligible patients, 3088 were enrolled in the
study. These patients included 200 with uncontrolled hypertension who were taking three or more classes of antihypertensive medications,
including a diuretic, and 44 with controlled hypertension who were taking four or more antihypertensive medications
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Table 1 Baseline characteristics of patients with resistant and nonresistant hypertension
Characteristics Resistant (N = 244) Nonresistant (N = 2844) P-value Total (N = 3088)
Age, yr 64.7 ± 12.7 64.3 ± 11.2 0.621 64.3 ± 11.3
Male, n (%) 135 (55.3) 1355 (47.6) 0.021 1490 (48.3)
Average systolic BP, mmHg 146.6 ± 15.6 130.4 ± 14.5 <0.001 131.7 ± 15.2
Average diastolic BP, mmHg 83.9 ± 11.4 79.0 ± 9.7 <0.001 79.4 ± 10.0
Waist, cm 91.4 ± 9.2 88.3 ± 8.9 <0.001 88.5 ± 9.0
Abdominal obesity, n (%) 163 (66.8) 1584 (55.7) 0.001 1747 (56.6)
Body mass index, kg/m2 26.2 ± 3.3 25.0 ± 3.1 <0.001 25.1 ± 3.2
Smoking 0.004c
Current smoker, n (%) 62 (25.4) 491 (17.3) 0.001b 553 (17.9)
Ex-smoker, n (%) 58 (23.8) 668 (23.5) 726 (23.5)
None, n (%) 124 (50.8) 1685 (59.2) 1809 (58.6)
Diabetes and prediabetes 0.046c
Diabetes mellitus, n (%) 86 (35.2) 825 (29.0) 0.04b 911 (29.5)
Impaired fasting glucose, n (%) 112 (45.9) 1391 (48.9) 1503 (48.7)
Non-diabetes, n (%) 46 (18.9) 628 (22.1) 674 (21.8)
Fasting plasma glucose, mg/dL 112.2 ± 2.4 106.9 ± 0.7 0.031 107.3 ± 36.8
HbA1c, % 6.31 ± 1.06 6.15 ± 0.95 0.017 6.16 ± 0.96
Serum creatinine, mg/dL 1.09 ± 0.26 1.03 ± 0.25 <0.001 1.03 ± 0.25
Estimated GFR, mL/min/1.73 m2 66.6 ± 17.5 69.3 ± 15.7 0.02 69.1 ± 15.8
< 60, n (%) 77 (32.1) 621 (22.2) <0.001 698 (23.0)
Albumin:creatinine ratio, mg/g 82.0 ± 424.2 53.2 ± 240.8 0.296 55.5 ± 260.0
< 30, n (%) 177 (72.5) 2179 (76.6) 2356 (76.3)
30–300, n (%) 56 (23.0) 567 (19.9) 623 (20.2)
> 300, n (%) 11 (4.5) 98 (3.4) 109 (3.5)
LVH on ECG, n (%) 21 (8.7) 110 (3.9) <0.001 131 (4.2) c
Lipid profiles
Total cholesterol, mg/dL 182.5 ± 36.7 183.1 ± 36.2 0.812 183.0 ± 36.2
LDL, mg/dL 103.1 ± 33.5 105.7 ± 32.5 0.243 105.5 ± 32.6
HDL, mg/dL 44.9 ± 11.1 46.9 ± 12.2 0.014 46.7 ± 12.2
Triglyceride, mg/dL 191.6 ± 144.1 162.3 ± 100.1 0.002 164.6 ± 104.5
Dyslipidemia, n (%) 48 (19.7) 645 (22.7) 0.28 693 (22.4)
Total number of classes of medications 3.34 ± 0.48 1.71 ± 0.70 <0.000 1.84 ± 0.82
Baseline antihypertensive medications
Diuretics, n (%) 242 (99.2) 907 (31.9) <0.001 1149 (37.2)
Calcium channel blocker, n (%) 213 (87.3) 1533 (53.9) <0.001 1746 (56.5)
ACE inhibitor/ARB, n (%) 237 (97.1) 1926 (67.7) <0.001 2163 (70.0)
β-blocker, n (%) 118 (48.4) 480 (16.9) <0.001 598 (19.2)
α-blocker, n (%) 4 (1.6) 8 (0.2) 0.005a 10 (0.3)
Central acting drugs, n (%) 0 (0) 0 (0) 0 (0)
Direct vasodilator 2 (0.8) 2 (0.1) 0.034a 4 (0.1)
Comorbidities
Stroke, n (%) 16 (6.6) 118 (4.1) 0.076 134 (4.3)
Cardiovascular disease, n (%) 43 (17.6) 306 (10.8) 0.001 350 (11.3)
Renal disease, n (%) 11 (4.5) 121 (4.3) 0.851 132 (4.2)
Peripheral arterial disease, n (%) 16 (6.6) 119 (4.2) 0.082 136 (4.4)
Abbreviations: α-blocker alpha blocker, ACE inhibitor angiotensin-converting enzyme inhibitors, ARB angiotensin-II receptor blockers, β-blocker beta-blocker, BP
blood pressure, ECG electrocardiograph, GFR glomerular filtration rate, HbA1c glycosylated hemoglobin, HDL high-density lipoprotein, LVH left ventricular hyper-
trophy, LDL low-density lipoprotein
aFisher’s exact test was used
bRate of the variable was compared with the rest
cThe results of the one-way ANOVA with Bonferroni’s test for post-hoc comparisons
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by calcium channel blockers (CCB, 56.5 %). In comparison
to those with non-RH, patients with RH were more likely
to be men and to have significantly higher BMI and in-
creased blood levels of fasting plasma glucose and HbA1c.
Blood pressure and medications
The prevalence of RH in all hypertensive patients was
7.9 % (N = 244, grey boxes in Fig. 1), 19.8 % of patients
were prescribed three or more classes of antihyperten-
sive medications (N = 610). Systolic and diastolic blood
pressure were well controlled in 2119 patients (68.6 %).
Among patients who were prescribed any medication,
71.3 % (N = 801) had controlled blood pressure. The per-
centage of patients with controlled blood pressure varied
according to the number of medications prescribed: one
medication, 69.6 % (N = 916); two medications, 63.6 %
(N = 334); three medications; and four or more medi-
cations, 51.8 % (N = 44, Fig. 2). Among patients with
RH, the most commonly prescribed medications were
diuretics (99.2 %), ACE inhibitors/ARBs (97.1 %), and
calcium channel blockers (87.3 %).
Cardiovascular risk factors
Compared with patients with non-RH, those with RH
had more cardiovascular risk factors at baseline, such as
abdominal obesity, smoking, diabetes mellitus, and renal
impairment. Significantly more RH patients were current
smokers, than were non-RH patients (25.4 and 17.3 %,
respectively; P = 0.001). Renal impairment, defined as an
estimated glomerular filtration rate (GFR) of <60 mL/
min/1.73 m2, was more prevalent among RH patients as
it was among non-RH patients (32.1 % versus 22.2 %, re-
spectively). However, the prevalence of dyslipidemia did
not significantly differ between patients with RH and
those with non-RH.
Target organ damage and comorbidities
Target organ damage to the heart and/or the kidney was
observed in 1284 patients (41.7 % of total participants,
Fig. 3). Target organ damage was more prevalent in RH
patients (P < 0.001). Among total participants, 131 pa-
tients (4.2 %) had cardiac involvement, which was defined
by LVH on electrocardiography, and 1217 patients
(39.6 %) had renal involvement, which was defined by an
estimated GFR < 60 mL/min/1.73 m2 or an albumin to
creatinine ratio of ≥30 μg/mg (Table 2). Among patients
with RH, the prevalence of LVH and decreased estimated
GFR were significantly higher (both P < 0.001). Although
the prevalence of microalbuminuria and/or overt protein-
uria were not statistically significant between two groups,
these conditions tended to be higher among patients with
RH than among those with non-RH.
Predictors of resistant hypertension
Table 3 shows the results of multivariate logistic regres-
sion analysis, which were adjusted for significant vari-
ables in a univariate analysis. The significant variables
identified as predictors of RH among all hypertensive
patients, in increasing order of odds ratio were: electro-
cardiographic LVH, current smoking, renal impairment
(estimated GFR <60 mL/min/1.73 m2), abdominal obes-
ity (waist circumference ≥90 in men and ≥85 in women),
Fig. 2 The proportion of patients with controlled and uncontrolled hypertension taking one, two, three, or four or more classes of medication.
Among patients with controlled hypertension, 61.5 % (N = 24) took no medication, 71.3 % (N = 801) took one type of medication, 69.6 %
(N = 916) took two, 63.6 % (N = 334) took three, and 51.8 % (N = 44) took four or more
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and the presence of cardiovascular disease. Electrocar-
diographic LVH predicted the greatest odds of RH (odds
ratio [OR] 2.23, 90 % CI 1.34–3.71). Gender, microalbu-
minuria or macroalbuminuria, and diabetes mellitus did
not significantly differ between the groups.
Discussion
This observational and cross-sectional study surveyed
demographic findings, clinical characteristics, and anti-
hypertensive medication classes in hypertensive patients
at 230 primary care clinics in Korea. The purpose of our
study was to evaluate the prevalence of the patients who
corresponded to the criteria of RH, and to determine the
demographic and clinical features that distinguish high-
risk individuals who develop RH from all hypertensive
patients.
In this study, the prevalence of RH was 7.9 % (N = 244),
which is lower than the prevalence reported in some
studies. This phenomenon may be explained by the differ-
ent conditions of our study, as compared with other stud-
ies. In the Controlled Onset Verapamil Investigation of
Cardiovascular Endpoints (CONVINCE) trial and the
Antihypertensive and Lipid Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT), the prevalence of RH
was 18 and 15 %, respectively. Those data were examined
from patients who were 55 years or older who had one or
more additional cardiovascular risk factors [13, 14]. In an-
other study, target blood pressure was defined as less than
130/80 mmHg if the patients had diabetes mellitus or kid-
ney disease, which led to 9.1 % of patients defined as hav-
ing RH [6]. In our study, however, patients were 18 years
or older and did not require any cardiovascular risk factor
for enrollment. We used the new Joint National Commit-
tee 8 guideline that define target blood pressure (<140/
90 mmHg) to be the same for patients with and without
diabetes mellitus and kidney disease [8]. Another hypoth-
esis, which may help explain the lower prevalence of RH
in our study, is that those patients with uncontrolled
hypertension may have already been referred to the hos-
pital for further evaluation and clinical management.
According to the 2013 Report of Assessment for quality of
hypertension treatment in Korea, about 30 % of hyperten-
sive patients receive medications from hospitals, rather
than primary clinics [15]. Thus, the prevalence of RH at
primary clinics may be lower than that of RH at hospitals.
Moreover, the prevalence of RH may be overestimated
at primary clinics. In the present study, the prevalence
of uncontrolled hypertension was 31.4 %, much higher
than that reported in other studies (13–17 %) [5]. Forced
titration of antihypertensive medications by the phys-
ician may also contribute to the improved control rate
of hypertension. If patients had uncontrolled RH and
were taking three medications, including a diuretic, they
would be reallocated from the RH group to the con-
trolled non-RH group; thus, the prevalence of RH would
be decreased.
We showed several predictors to be associated with RH:
electrocardiographic LVH, renal impairment, current
smoker, abdominal obesity, and cardiovascular disease. In
particular, hypertensive patients with electrocardiographic
LVH were 2.3 odds (1.39–3.80, 95 % confidence interval)
more likely to have RH compared to those without
Fig. 3 Target organ damage among patients with resistant and
nonresistant hypertension. Cardiac and renal target organ damage was
more frequently detected in patients with resistant hypertension than
in those with nonresistant hypertension (P < 0.001)
Table 2 Prevalence of hypertensive target organ damage among participants
n (%) Resistant Nonresistant P-value Total
Cardiac damage 21 (8.7) 110 (3.9) <0.001 131 (4.2)
LVH on ECG 21 (8.7) 110 (3.9) <0.001 131 (4.2)
Renal damage 120 (49.6) 1097 (38.7) 0.001 1217 (39.6)
Estimated GFR <60 77 (32.1) 621 (22.2) <0.001 698 (23.0)
Albumin:creatinine ratio ≥30 67 (27.8) 665 (23.8) 0.158 732 (24.1)
Abbreviations: ECG electrocardiograph, GFR glomerular filtration rate, LVH left ventricular hypertrophy
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electrocardiographic LVH. LVH is not only one of the
most important subclinical cardiac alterations that result
from continuous high blood pressure but also represents a
target organ damage [16]. In addition to a chronic pres-
sure overload, overexpression of humoral and hormonal
factors are also attributed to the development of cardiac
hypertrophy in patients with RH and obstructive sleep
apnea, hyperaldosteronism, or both [17]. Although it has
yet to be established whether LVH aggravates hyperten-
sion, if patients with uncontrolled hypertension have elec-
trocardiographic LVH, further evaluation for the attributed
causes of LVH may be needed to improve the clinical man-
agement of hypertension.
The prevalence of RH in the subgroup with renal im-
pairment (N = 698) was 11.0 %, in our study. Previous
studies have reported the prevalence of RH to be 50 %
or more [18]. Chronic renal parenchymal disease has
been ascertained as the most common identifiable sec-
ondary cause of RH. Possible mechanisms, by which de-
creased renal function leads to development of RH,
include the retention of sodium and fluid and the up-
regulation of the renin-angiotensin system [19, 20].
Thus, the use of diuretics and ACE inhibitors or ARBs
should be considered in patients with increased serum
creatinine or estimated GFR.
Lifestyle modifications, such as weight reduction and
smoking cessation, may also help improve hypertension
management. Although the exact mechanism by which
obesity increases blood pressure is not well understood,
excess weight gain has been reported as the best pre-
dictor for the development of hypertension [21]. Obesity
can lead to increased renal sodium reabsorption and
renal injury through the activation of the renin-
angiotensin system and increased sympathetic tone [22].
Identifying individuals at high risk of developing RH,
who have electrocardiographic LVH, renal impairment,
abdominal obesity, current smoking, or cardiovascular
disease, is important for the selection of appropriate
antihypertensive medications. Difficulty in controlling
blood pressure in patients with the aforementioned
predictors should prompt earlier consideration of forced
titration of medications and evaluation for secondary
hypertension.
This study has some limitations. First, drug adherence
was not measured accurately. Poor adherence to antihy-
pertensive medications is a well-known, major cause of
failure to reach target blood pressure [23]. However, pill
count and patient education were performed at each
visit to the clinic. Second, although we excluded patients
with a history of secondary or white-coat hypertension
from the initial recruiting, estimation of the prevalence
of pure RH was not perfect. It was difficult to perform
sophisticated examinations for all patients with uncon-
trolled hypertension in the primary care setting. The
final objective of this study was to manage hypertension
effectively by identifying patients who corresponded with
the criteria of RH. If secondary or white-coat hyperten-
sion is in doubt, referral to a hospital or hypertension-
specialized institution may be indicated. However, the
results of our study are valuable because they represent
the first investigation of RH at primary clinics in Korea,
and are robust, in that they are derived from 3088
patients and 247 primary physicians.
Conclusions
The prevalence of RH at primary clinics in Korea was
7.9 %, which is relatively low when compared with the
findings of studies conducted in other countries. Predic-
tors for increased risk of RH were electrocardiographic
LVH, renal impairment, current smoking, abdominal
obesity, and the presence of cardiovascular disease.
Therefore, these predictors may be helpful for detecting
risk of RH and for improving the efficiency of clinical
management for hypertension by forced titration or
selection of drugs.
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Table 3 Predictors of resistant hypertension at primary clinics
(N = 3088)
Variables Adjusted Odds Ratioa 95 % CI P-value
LVH on ECG 2.23 1.34–3.71 0.002
Current smoker 1.75 1.27–2.40 0.001
Estimated GFR <60 1.65 1.23–2.22 0.001
Abdominal obesity 1.60 1.20–2.13 0.001
Cardiac disease 1.50 1.04–2.17 0.032
Abbreviations: ECG echocardiograph, GFR glomerular filtration rate, LVH left
ventricular hypertrophy
aThe result of the binary logistic regression analysis included significant
variables for men, abdominal obesity, smoking, diabetes mellitus,
electrocardiographic LVH, estimated GFR < 60 mL/min/1.73 m2,
microalbumuria/macroalbuminuria and cardiovascular disease
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